Background Image

Biomea Partners

Biomea is cooperating with several leading global contract research organizations to support the drug development process of our proprietary designed medicines.​​
Screenshot Screenshot

Biomea entered into a development agreement with the Aptuit Corporation, which merged recently with the Evotec AG. The agreement includes a broad range of development services to support pre-clinical oncology programs and their advancement to the investigational new drug development (IND) stage. Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions by applying scientific excellence and employing a large team of some of the foremost scientific professionals in the industry. Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Evotec operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases.

Screenshot

Biomea entered into a development agreement with the Aptuit Corporation, which merged recently with the Evotec AG. The agreement includes a broad range of development services to support pre-clinical oncology programs and their advancement to the investigational new drug development (IND) stage. Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions by applying scientific excellence and employing a large team of some of the foremost scientific professionals in the industry. Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Evotec operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases.

Screenshot

Biomea also contracted with WuXi AppTec for drug development services. WuXi AppTec is a leading global pharmaceutical and biopharmaceutical drug development company. WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process to shorten the discovery and development time. WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.